Search Results
Your search for ,foR matches 33051 pages
Showing 30701 - 30750AACR 2015: Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes
Combination treatment with the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the investigational phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade...
AACR 2015: Subgroup of Men With Metastatic Prostate Cancer Respond to Olaparib Treatment
Men with metastatic, castration-resistant prostate cancer who had mutations in genes linked to repair of damaged DNA were significantly more likely to respond to treatment with olaparib (Lynparza) compared with patients who had the disease without these mutations. These findings from the first...
AACR 2015: Dual mTOR Inhibitor-Fulvestrant Combination Feasible, With Clinical Benefit for Advanced Breast Cancer Patients
The dual mTOR inhibitor AZD2014, when combined with the hormonal therapy fulvestrant (Faslodex), was found to be safe in patients with advanced estrogen receptor–positive breast cancer, and some of them experienced clinical benefit from the drug combination, according to phase I clinical...
AACR 2015: Metformin Use May Not Improve Pancreatic Cancer Survival
Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma in a retrospective cohort study presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract LB-183). “The diabetes drug metformin is being used in some cancer treatment...
Study Examines Impact of Hospital Volume on Complication Rates in Patients Undergoing Robotic Prostate Surgery
A disincentive for hospitals that have invested in expensive technology for robotic surgery may be jeopardizing prostate cancer patients who seek out the procedure, concluded a study published by Sammon et al in BJU International. The study compared complication rates in hospitals with low...
Frequency of Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer Not Meeting Criteria for Li-Fraumeni Syndrome
In a study reported in JAMA Oncology, Yurgelun et al identified germline TP53 mutations in multiple patients with early-onset colorectal cancer from the Colon Cancer Family Registry who did not meet clinical criteria for Li-Fraumeni syndrome. Li-Fraumeni syndrome is associated with increased risk...
AACR 2015: Black Women Found to Have Denser Breast Tissue Than White Women
Breast density, which is associated with breast cancer risk, was found to be higher in black women than white women when measured using novel quantitative methods, according to research presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract 2770). “Since...
AACR 2015: HPV Vaccine Provides Protection at Multiple Sites, Even Among Some Previously Exposed Patients
Vaccination of women aged 18 to 25 with the human papillomavirus (HPV) vaccine resulted in strong protection against future infection at three anatomic sites among women without prior HPV exposure and may still offer some protection in those with evidence of prior exposure. These findings were...
AACR 2015: Combining Two Investigational Immunotherapy Drugs Safe, With Early Signs of Effectiveness
Combining the immunostimulatory anti-CD40 monoclonal antibody CP-870,893 with the immune checkpoint inhibitor tremelimumab was found to be safe, with clinical evidence of response in patients with advanced melanoma, according to phase I clinical trial data presented at the AACR Annual Meeting 2015, ...
AACR 2015: Investigational PD-L1–Targeted Immunotherapy Safe for Patients With Triple-Negative Breast Cancer, Effective in Some
The investigational immunotherapy MPDL3280A was safe, tolerable, and showed early signs of durable clinical activity in patients with metastatic triple-negative breast cancer, according to data from a first-in-human phase I clinical trial presented at the AACR Annual Meeting 2015, held April 18 to...
AACR 2015: Improved Responses With Ipilimumab-Nivolumab Combination vs Ipilimumab Alone in Advanced Melanoma
Giving the two immunotherapies ipilimumab (Yervoy) and nivolumab (Opdivo) simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment, according to phase II clinical trial data presented at the AACR Annual Meeting 2015,...
AACR 2015: U.S. Breast Cancer Cases Expected to Increase by as Much as 50% by 2030
The total number of breast cancer cases in the United States is forecast to be 50% greater in 2030 than it was in 2011, when invasive and in situ or screening-detected cancers are counted together. This increase is predicted to be driven mostly by a marked increase in cases of estrogen...
AACR 2015: Pembrolizumab Safe, With Signs of Clinical Benefit, for Patients With Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda) was safe, tolerable, and yielded robust antitumor responses in patients with malignant pleural mesothelioma, according to data from the phase Ib KEYNOTE-028 clinical trial presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract CT103)....
AACR 2015: New Immunotherapy Yields Long-Lasting Responses in Some Patients With Advanced Melanoma
A first-in-class immunotherapy called IMCgp100 yielded durable responses in patients with advanced cutaneous melanoma and those with advanced ocular melanoma, according to data from a phase I/IIa clinical trial presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract ...
AACR 2015: Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers
Patients with advanced cancers who received mesothelin-directed chimeric antigen receptor–modified T cells (CART-meso), a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood...
Obesity Significantly Increases Prostate Cancer Risk in African American Men
Obesity in black men substantially increased the risk of low- and high-grade prostate cancer, whereas obesity in white men moderately reduced the risk of low-grade cancer and only slightly increased the risk of high-grade cancer, according to the first large, prospective study to examine how race...
Excessive All-Cause and Second Primary Malignancy-Related Mortality and Frequent Late Morbidity in Hodgkin Lymphoma Patients Treated During Adulthood
In a single-institution study reported in the Journal of the National Cancer Institute, Matasar et al found that Hodgkin lymphoma patients treated during adulthood were at increased risk of all-cause and second primary malignancy mortality compared with SEER (Surveillance, Epidemiology, and...
AACR 2015: Pembrolizumab Shows Promise in Non–Small Cell Lung Cancer
The immunotherapy pembrolizumab (Keytruda) was found to be safe and yielded durable responses in patients with advanced, non–small cell lung cancer (NSCLC). Those with high levels of the protein PD-L1 in their tumors had better clinical outcomes, according to phase I KEYNOTE-001 clinical...
AACR 2015: Pembrolizumab Is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial
In the first randomized trial to compare two U.S. Food and Drug Administration–approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab (Keytruda) yielded significantly better treatment outcomes than ipilimumab (Yervoy) for all endpoints...
AACR 2015: New T Cell–Based Immunotherapy Shows Promise for Lethal Stem Cell Transplant Complication
More than 60% of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was nonresponsive to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus–specific cytotoxic T-lymphocyte (EBV-CTL) therapy....
Glembatumumab Vedotin Appears Active in Heavily Treated Advanced Glycoprotein NMB–Overexpressing Breast Cancer and Triple-Negative Disease
In the randomized phase II EMERGE study reported in the Journal of Clinical Oncology, Yardley et al found that the anti–glycoprotein NMB (gpNMB) antibody-drug conjugate glembatumumab vedotin may improve response rate over alternative chemotherapy in patients with advanced refractory breast...
Do Survival Gains Match More Intense Treatment in Younger Patients With Colon Cancer?
In a study reported in JAMA Surgery, Kneuertz et al found that the more frequent stage-specific use of adjuvant chemotherapy in younger patients with colon cancer did not appear to produce commensurate benefit in survival compared with outcomes in older patients. Study Details The study was a...
Evidence Grows That Melanoma Drugs May Benefit Some Lung Cancer Patients
A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva (Abstract 21PD_PR). Oliver Gautschi, MD, a...
One-Quarter of Advanced Lung Cancer Patients Tested for EGFR Mutations Started on First-Line Therapy Before Test Results Available
Almost one in four patients (24%) with advanced lung cancer in Europe, Asia, and the United States are not receiving EGFR test results before being started on treatment, researchers reported at the European Lung Cancer Conference (ELCC) in Geneva (Abstract LBA2_PR). This lack of test results may...
Circulating Tumor DNA May Be Used to Detect EGFR Mutations in Lung Cancer
Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimize treatment when tumor tissue is not available, an international group of researchers has reported at the European Lung Cancer Conference (ELCC) in Geneva...
Physical Activity Helps Cancer Survivors Fend Off Side Effects
Three or more hours of walking per week can boost the vitality and health of prostate cancer survivors. Men and women who have survived colorectal cancer and are regular walkers also reported lower sensations of burning, numbness, tingling, or loss of reflexes that many often experience after...
Statin Use Is Associated With Reduced Risk of Primary Liver Cancer in Low-Prevalence Setting
In a study reported in the Journal of the National Cancer Institute, McGlynn et al found that statin use was associated with a reduced risk of primary liver cancer in a setting of low liver cancer prevalence. Other studies have shown a preventive benefit of statin therapy in regions of the world...
Study Finds Large Disparities in Survival Among Adolescents and Young Adults With Differentiated Thyroid Cancer
A large, diverse study of 16,827 adolescents and young adults with differentiated thyroid cancer has found that African Americans and Hispanics were six times and three times more likely, respectively, to die of their cancer than Caucasians. Residing in low-socioeconomic neighborhoods, insurance...
Ibrutinib Is Highly Active in Previously Treated Waldenström’s Macroglobulinemia
In a study reported in The New England Journal of Medicine, Treon et al found that ibrutinib (Imbruvica) was highly active and produced durable responses in patients with previously treated Waldenström’s macroglobulinemia. Response rates were highest in patients with MYD88 mutation and...
Similar Outcomes With Laparoscopic vs Open Resection in Rectal Cancer
In the COLOR II study reported in The New England Journal of Medicine, Bonjer et al found similar rates of locoregional recurrence and disease-free and overall survival with laparoscopic vs open resection of rectal cancer. Study Details In the trial, 1,044 patients from 30 sites in 8 countries in ...
ASCO Issues Statement Praising the Senate Repeal of SGR
In a statement, the American Society of Clinical Oncology praised the U.S. Senate’s 92-to-8 approval of legislation to repeal the Sustainable Growth Rate formula. ASCO President Peter Paul Yu, MD, FACP, FASCO, said, “Today's courageous vote by the U.S. Senate to finally end the...
Less Than 95% Adherence to Mercaptopurine Maintenance Associated With Nearly Threefold Increased Risk of Relapse in Pediatric ALL
In a Children’s Oncology Group study (COG-AALL03N1) reported in JAMA Oncology, Bhatia et al found that < 95% adherence to mercaptopurine treatment was associated with a nearly threefold increase in the risk of relapse in children with acute lymphoblastic leukemia (ALL). Among adherent...
Circulating Tumor Cell Count and LDH Level as Patient-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
In an analysis reported in the Journal of Clinical Oncology, Scher et al found that circulating tumor cell count and LDH level served as an individual-level surrogate for survival among patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate (Zytiga) plus...
No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma
In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....
More Extensive Lymph Node Clearance During Surgery for Esophageal Cancer May Not Improve Survival
A population-based cohort study indicates that “more extensive lymph node clearance during surgery for esophageal cancer may not improve survival,” van der Schaaf et al reported in the Journal of the National Cancer Institute. “These results challenge current clinical guidelines,...
Patients With Relapsed or Refractory CLL Who Discontinue Ibrutinib Early Have Poor Outcomes
Most patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who discontinued ibrutinib (Imbruvica) early “were difficult to treat and had poor outcomes,” according to a study of patients enrolled in four different clinical trials of ibrutinib, with or without rituximab...
Identifying Processes That Lead to Discontinuation of Chemotherapy for Patients With NSCLC at End of Life
According to a recent study by Perl et al published in the Journal of Oncology Practice, the administration of chemotherapy near death is recognized by patients, their families, and oncologists as “aggressive and poor-quality care.” Despite this, rates of end-of-life chemotherapy have...
Study Finds Price of Cancer Drugs Varies Widely Based on Who’s Paying
Uninsured cancer patients are paying anywhere from 2 to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill. These findings were published by Dusetzina et al in Health Affairs. Major Discrepancies Researchers led...
Study Finds Link Between Muscle-Building Supplements and Testicular Cancer
Men who reported taking muscle-building supplements, such as pills and powders with creatine or androstenedione, reported a significantly higher likelihood of having developed testicular cancer than men who did not use such supplements, according to a study by Li et al in the British Journal of...
Regional-Level Correlation of Inappropriate Prostate Imaging and Inappropriate Breast Imaging
In a study reported in JAMA Oncology, Makarov et al found that hospital referral regions marked by higher rates of inappropriate imaging in patients with low-risk breast cancer also had high rates of inappropriate prostate imaging in patients with low-risk prostate cancer. Inappropriate imaging...
Platinum Monotherapy Particularly Active in BRCA1/2-Mutant Metastatic Triple-Negative Breast Cancer
In the phase II TBCRC009 trial reported in the Journal of Clinical Oncology, Isakoff et al found that platinum monotherapy was active in treatment of metastatic triple-negative breast cancer, particularly in cases with BRCA1/2 mutation, and that an assay of genomic instability characteristic of...
Neoadjuvant Iniparib Plus Gemcitabine-Carboplatin Is Active in Early Triple-Negative and BRCA1/2-Mutant Breast Cancer
In the phase II PrECOG 0105 study reported in the Journal of Clinical Oncology, Telli et al found that neoadjuvant iniparib plus gemcitabine-carboplatin was active in early-stage triple-negative and BRCA1/2-mutant breast cancer. Higher score on a homologous recombination deficiency–loss of...
Long-Term Study Shows Stress Management Techniques Improve Mood and Quality of Life for Breast Cancer Patients
A new study showed that providing women with skills to manage stress early in their breast cancer treatment can improve their mood and quality of life many years later. Published by Stagl et al in Cancer, the findings suggest that women given the opportunity to learn stress management techniques...
Increasing Number of Boys Vaccinated Against HPV Could Protect More People at the Same Price
Public health programs that devote a portion of their funding to encourage more boys to be vaccinated against human papillomavirus (HPV)—rather than merely attempting to raise coverage among girls—may ultimately protect more people for the same price, a study from Duke University...
Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells
As reported in the Journal of Clinical Oncology, Stevanovíc et al observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients with metastatic cervical ...
Durable Responses With Nivolumab in Previously Treated Advanced Renal Cell Carcinoma
In a phase I cohort-expansion study reported in the Journal of Clinical Oncology, McDermott et al found that nivolumab (Opdivo) produced durable responses in patients with previously treated advanced renal cell carcinoma. Responses continued after nivolumab discontinuation in some patients. Study...
NPM1-Positive/FLT3-ITD–Negative Genotype Not Associated With Significantly Better Prognosis in Older AML Patients
In a study reported in the Journal of Clinical Oncology, Ostronoff et al found that the presence of the NPM1-positive/FLT3-internal tandem duplication (ITD)–negative genotype—which is recognized as a marker of better prognosis in younger patients with acute myeloid leukemia—was...
Cancer Experts Find Too Many People Are Being Screened, Diagnosed, and Treated for Disease
A recent commentary published in Annals of Internal Medicine discusses the paradoxical finding that most patients are at below-average risk of disease and can expect to experience less-than-average benefits from a treatment. Yet, argue Vickers et al, too many people are being screened, diagnosed,...
Key Tumor-Cell Proliferation Mechanism Identified in Pediatric Bone Cancers
A particular molecular pathway permits stem cells in pediatric bone cancers to grow rapidly and aggressively, according to researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. These findings were published by Basu-Roy et al in Nature Communications. Study...
Stereotactic Body Radiotherapy Plus Cetuximab Appears Safe, Effective in Previously Irradiated Recurrent Head and Neck Squamous Cell Carcinoma
In patients with previously irradiated recurrent squamous cell carcinoma of the head and neck, the combination of stereotactic body radiation therapy plus cetuximab (Erbitux) appears to be safe and effective, according to a study by Vargo et al in the International Journal of Radiation Oncology...
